We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Neurology

Journal Scan / Review · September 08, 2020

Aducanumab, Gantenerumab, BAN2401, and ALZ-801 for Alzheimer's Disease

Alzheimer's Research &Therapy

 

Additional Info

Alzheimer's Research &Therapy
Aducanumab, Gantenerumab, BAN2401, and ALZ-801—The First Wave of Amyloid-Targeting Drugs for Alzheimer's Disease With Potential For Near Term Approval
Alzheimers Res Ther 2020 Aug 12;[EPub Ahead of Print], M Tolar, S Abushakra, JA Hey, A Porsteinsson, M Sabbagh

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading